



05 NOV 2004

162162

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
20 November 2003 (20.11.2003)

PCT

(10) International Publication Number
WO 03/095420 A1(51) International Patent Classification⁷: **C07C 275/32**,
275/42, 275/40, A61K 31/17, A61P 13/00, 29/00(74) Common Representative: **BAYER AKTIENGESELLSCHAFT**; 51368 Leverkusen (DE).(21) International Application Number: **PCT/EP03/04395**(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 28 April 2003 (28.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0210512.0 8 May 2002 (08.05.2002) GB
0227262.3 21 November 2002 (21.11.2002) GB(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).(71) Applicant (*for all designated States except US*): **BAYER AKTIENGESELLSCHAFT** [DE/DE]; 51368 Leverkusen (DE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **YURA, Takeshi** [JP/JP]; 4-8-1, Suzaku, Nara-shi, Nara 631-0806 (JP). **MOGI, Muneto** [JP/JP]; 5-10-57-102, Daianji, Nara-shi, Nara 630-8133 (JP). **URBAHNS, Klaus** [DE/JP]; 6-3-1-301, Kusugaoka-cho, Nada-ku, Kobe-shi, Hyogo 657-0024 (JP). **FUJISHIMA, Hiroshi** [JP/JP]; 3-23-25, Sakyo, Nara-shi, Nara 631-0801 (JP). **MASUDA, Tsutomu** [JP/JP]; 3-15-6-6A, Jingu, Nara-shi, Nara 631-0804 (JP). **MORIWAKI, Toshiya** [JP/JP]; 2-25-4, Kitayamato, Ikoma-shi, Nara 630-0121 (JP). **YOSHIDA, Nagahiro** [JP/JP]; 5-18-15, Saganakadai, Kizu-cho, Soraku-gun, Kyoto 619-0223 (JP). **KOKUBO, Toshio** [JP/JP]; 3-15-18B, Jingu, Nara-shi, Nara 631-0804 (JP). **SHIROO, Masahiro** [JP/JP]; 1-3-17, Shikanodai-Minami, Ikoma-shi, Nara 630-0113 (JP). **TAJIMI, Masaomi** [JP/JP]; 1-8-7 Sakuragaoka, Seika-cho, Soraka-gun, Kyoto 619-0232 (JP). **TSUKIMI, Yasuhiro** [JP/JP]; 2-10-1, Kukuchi, Amagasaki-shi, Hyogo 661-0977 (JP). **YAMAMOTO, Noriyuki** [JP/JP]; 6-6-1-3-404, Jingu, Nara-shi, Nara 631-0804 (JP).**Declaration under Rule 4.17:**— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)***Published:**— *with international search report**For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*(54) Title: **HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES**

(57) Abstract: This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algosia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence, inflammatory disorders such as asthma and COPD.

WO 03/095420 A1



ACTION